AbbVie's Allergan Seeks FDA OK of AGN-190584 in Presbyopia
February 25 2021 - 8:58AM
Dow Jones News
By Colin Kellaher
AbbVie Inc.'s Allergan unit on Thursday said it filed a new-drug
application with the U.S. Food and Drug Administration for
AGN-190584, an ophthalmic solution for the treatment of the common
vision condition presbyopia.
Allergan said AGN-190584, if approved, would be the first eye
drop to treat presbyopia, a progressive condition that reduces the
eye's ability to focus on near objects and usually impacts people
after age 40.
Allergan, which noted that roughly 128 million adults in the
U.S. experience presbyopia, said it expects the FDA to act on the
application by the end of the year.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 25, 2021 08:43 ET (13:43 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Mar 2024 to Apr 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Apr 2023 to Apr 2024